Actively Recruiting
Evaluating Circulating BDNF Levels and Atrial Cardiomyopathy in Patients Undergoing Ablation for Persistent Atrial Fibrillation
Led by Centre Hospitalier Universitaire Dijon · Updated on 2026-10-26
150
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Atrial fibrillation AF is a common heart rhythm disorder linked to serious risks like strokes and heart failure. This research focuses on atrial cardiomyopathy ACM, a broader heart condition that contributes to AF. The study aims to better understand ACM by examining patients with persistent AF undergoing ablation, a treatment to correct heart rhythm, and investigating the relationship between brain-derived neurotrophic factor BDNF levels and heart tissue changes. Participants are patients scheduled for their first ablation procedure for persistent AF at a university hospital. The study observes blood samples to measure BDNF levels and uses cardiac computed tomography CT scans alongside electroanatomical mapping during ablation to assess heart tissue changes. These assessments occur before and during the ablation procedure, with follow-up measures planned one year later to track changes in BDNF and heart structure. Throughout the study, participants undergo blood draws to assess BDNF, CT scans to evaluate heart changes, and heart rhythm monitoring with Holter devices. Researchers will monitor the recurrence of AF from 3 to 12 months after ablation, correlating it with BDNF levels and heart remodeling. Clinical outcomes and rhythm changes will be observed over time, with the total study duration extending from the start date through to final assessments in 2029.
CONDITIONS
Brief Title
Association Between Circulating BDNF Levels and Atrial Cardiomyopathy in Patients Undergoing Ablation for Persistent Atrial Fibrillation
Research Team
C
Charles GUENANCIA
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here